These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14970933)

  • 1. Nonmyeloablative stem cell transplantation for lymphoma.
    Khouri IF; Champlin RE
    Semin Oncol; 2004 Feb; 31(1):22-6. PubMed ID: 14970933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
    Khouri IF; McLaughlin P; Saliba RM; Hosing C; Korbling M; Lee MS; Medeiros LJ; Fayad L; Samaniego F; Alousi A; Anderlini P; Couriel D; de Lima M; Giralt S; Neelapu SS; Ueno NT; Samuels BI; Hagemeister F; Kwak LW; Champlin RE
    Blood; 2008 Jun; 111(12):5530-6. PubMed ID: 18411419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
    Khouri IF; Keating M; Körbling M; Przepiorka D; Anderlini P; O'Brien S; Giralt S; Ippoliti C; von Wolff B; Gajewski J; Donato M; Claxton D; Ueno N; Andersson B; Gee A; Champlin R
    J Clin Oncol; 1998 Aug; 16(8):2817-24. PubMed ID: 9704734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.
    Tam CS; Khouri I
    Curr Hematol Malig Rep; 2007 Oct; 2(4):225-31. PubMed ID: 20425374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
    Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
    Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.